Equities

WDB coco Co Ltd

7079:TYO

WDB coco Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,730.00
  • Today's Change0.00 / 0.00%
  • Shares traded10.90k
  • 1 Year change-21.47%
  • Beta0.5203
Data delayed at least 20 minutes, as of Nov 11 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year WDB coco Co Ltd grew revenues 12.90% from 4.07bn to 4.60bn while net income improved 15.36% from 743.63m to 857.83m.
Gross margin41.93%
Net profit margin18.83%
Operating margin27.87%
Return on assets21.59%
Return on equity27.41%
Return on investment26.10%
More ▼

Cash flow in JPYView more

In 2024, WDB coco Co Ltd increased its cash reserves by 32.80%, or 656.68m. The company earned 859.44m from its operations for a Cash Flow Margin of 18.70%. In addition the company used 91.82m on investing activities and also paid 110.94m in financing cash flows.
Cash flow per share412.64
Price/Cash flow per share9.03
Book value per share1,597.93
Tangible book value per share1,503.76
More ▼

Balance sheet in JPYView more

WDB coco Co Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 2.66bn.
Current ratio5.09
Quick ratio5.08
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in JPY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 82.93% and 15.25%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Business Services industry pay a dividend. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
Div yield(5 year avg)1.05%
Div growth rate (5 year)--
Payout ratio (TTM)19.02%
EPS growth(5 years)24.68
EPS (TTM) vs
TTM 1 year ago
24.91
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.